Anorexia Clinical Trial
Official title:
Representations, Strategies and Identity Redefinition in the Recovery Process: Exploratory Study
In the recent context of deinstitutionalization and longitudinal studies pointing to a large
number of positive long-term outcommes for people affected by a psychiatric disorder
(schizophrenia, bipolar disorder, eating disorder, severe personality disorder, etc.), the
possibility of overcoming the consequences of a psychiatric pathology emerges as a solid
fact. Therefore, the existence of this possibility calls for the identification of the
determinants underlying of the various outcomes over time of those affected by a severe
psychiatric disorder, in particular those likely to underpin the most positive developments.
While it is well known from a medical point of view that certain dimensions affect the
prognosis of persons affected by a severe psychiatric disorder (such as the persistence of
negative symptoms or cognitive disorders in schizophrenic disorders), prognosis from a purely
medical perspective (and putting aside the role of the person and his environment) seems to
be able to account only for a modest proportion of the prognosis of people affected by a
serious psychiatric disorder.
It is this fact that has gradually led to the emergence of complementary models capable of
enriching the understanding of the determinants of the future of people affected by a severe
psychiatric disorder, in particular models inviting to separate "becoming of the person" from
the " psychiatric disorder "to take into account the" personal role of the person "in his or
her own healing. This perspective is the "recovery" perspective.
Recovery process is defined as a personal trajectory which includes the person's experiences
and the reactions of his / her environment following the installation of a psychiatric
disorder, which can support a mode of release of the status of "psychiatric patient".
Recovery thus implies an "approach underpinned by the understanding of the human response to
pathology" (Noiseux) and, one might add, of its environment.
However, while these studies point to a number of crucial dimensions involved in the recovery
of a severe psychiatric disorder, one of the important limitations of these studies is the
distance from any psychopathological consideration, thus setting aside the possibility of
specific processes of recovery depending of the pathology. The identification of recurrent
experiential logics specific to the various psychiatric disorders therefore appears to be an
important field of investigation. It would potentially be able to guide the development of
new therapeutic devices based on the recovery model.
1. Elaboration of a semi directed grid (exploratory phase)
2. Collection of individual narratives
3. Data analysis, according to IPA method (interpretative phenomenological analysis)
- On the basis of individual narratives
- On the basis of a focus group
4. Publication of results
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01501396 -
Megestrol Acetate With or Without Mirtazapine in Treating Cancer Patients With Weight Loss or Loss of Appetite
|
Phase 2 | |
Withdrawn |
NCT02793102 -
Sensory Workshops and Anorexia Nervosa
|
N/A | |
Active, not recruiting |
NCT01206335 -
Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia
|
Phase 2 | |
Completed |
NCT02524301 -
Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study
|
N/A | |
Active, not recruiting |
NCT00488072 -
Effects of Mirtazapine on Appetite in Advanced Cancer Patients
|
Phase 2 | |
Withdrawn |
NCT05039385 -
Exercise Program in Patients With Anorexia Nervosa (ESATRAL)
|
N/A | |
Completed |
NCT03097874 -
Adaptive Treatment for Adolescent Anorexia Nervosa
|
N/A | |
Completed |
NCT00031785 -
Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer
|
Phase 3 | |
Terminated |
NCT00535015 -
Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT00558558 -
Haelan and Nutrition in Cancer Patients
|
Phase 2 | |
Completed |
NCT00040885 -
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
|
Phase 3 | |
Completed |
NCT00006799 -
Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer
|
Phase 3 | |
Active, not recruiting |
NCT03637816 -
Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT04007900 -
Positive Affect Treatment (PAT) to Target Reward Mechanisms in Anorexia Nervosa
|
N/A | |
Completed |
NCT00735540 -
Clinical Diagnosis of Teenagers Admitted to Pediatric Departments
|
N/A | |
Completed |
NCT00046904 -
Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer
|
Phase 3 | |
Completed |
NCT04803305 -
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
|
Phase 1 | |
Completed |
NCT05708404 -
Outpatient Treatment of Severe and Enduring Anorexia Nervosa
|
||
Completed |
NCT03283488 -
Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.
|
Phase 2 | |
Recruiting |
NCT05503147 -
Sativex® and Gentamicin for Optimized Pharmagological Treatment in Older Patients (CanPan)
|
Phase 1 |